436 related articles for article (PubMed ID: 31717860)
21. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
[TBL] [Abstract][Full Text] [Related]
22. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
23. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
Dornas W; Lagente V
Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
[TBL] [Abstract][Full Text] [Related]
24. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
25. Alcoholic liver disease: the gut microbiome and liver cross talk.
Hartmann P; Seebauer CT; Schnabl B
Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
[TBL] [Abstract][Full Text] [Related]
26. Targeting the gut-liver-immune axis to treat cirrhosis.
Tranah TH; Edwards LA; Schnabl B; Shawcross DL
Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
[TBL] [Abstract][Full Text] [Related]
28. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
[TBL] [Abstract][Full Text] [Related]
29. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
30. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
[TBL] [Abstract][Full Text] [Related]
31. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
[TBL] [Abstract][Full Text] [Related]
32. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
33. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial proteins: intestinal guards to protect against liver disease.
Hendrikx T; Schnabl B
J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
[TBL] [Abstract][Full Text] [Related]
35. The shaping of gut immunity in cirrhosis.
Muñoz L; Caparrós E; Albillos A; Francés R
Front Immunol; 2023; 14():1139554. PubMed ID: 37122743
[TBL] [Abstract][Full Text] [Related]
36. [Gut microbiota and nonalcoholic steatohepatitis].
Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
[TBL] [Abstract][Full Text] [Related]
37. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
38. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
[TBL] [Abstract][Full Text] [Related]
39. Macrophages in the pathophysiology of NAFLD: The role of sex differences.
Ministrini S; Montecucco F; Sahebkar A; Carbone F
Eur J Clin Invest; 2020 Jun; 50(6):e13236. PubMed ID: 32294235
[TBL] [Abstract][Full Text] [Related]
40. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]